Cargando…

The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)

BACKGROUND: Recent genome-wide association studies have identified multiple loci that are associated with an increased risk of developing coronary artery disease (CAD). The impact of these loci on the disease severity and prognosis of ischemic heart failure due to CAD is currently unknown. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Haver, Vincent G, Verweij, Niek, Kjekshus, John, Fox, Jayne C, Wedel, Hans, Wikstrand, John, van Gilst, Wiek H, de Boer, Rudolf A, van Veldhuisen, Dirk J, van der Harst, Pim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412120/
https://www.ncbi.nlm.nih.gov/pubmed/25528061
http://dx.doi.org/10.1186/s12881-014-0140-3
_version_ 1782368610086289408
author Haver, Vincent G
Verweij, Niek
Kjekshus, John
Fox, Jayne C
Wedel, Hans
Wikstrand, John
van Gilst, Wiek H
de Boer, Rudolf A
van Veldhuisen, Dirk J
van der Harst, Pim
author_facet Haver, Vincent G
Verweij, Niek
Kjekshus, John
Fox, Jayne C
Wedel, Hans
Wikstrand, John
van Gilst, Wiek H
de Boer, Rudolf A
van Veldhuisen, Dirk J
van der Harst, Pim
author_sort Haver, Vincent G
collection PubMed
description BACKGROUND: Recent genome-wide association studies have identified multiple loci that are associated with an increased risk of developing coronary artery disease (CAD). The impact of these loci on the disease severity and prognosis of ischemic heart failure due to CAD is currently unknown. METHODS: We undertook association analysis of 7 single nucleotide polymorphism (rs599839, rs17465637, rs2972147, rs6922269, rs1333049, rs501120, and rs17228212) at 7 well established CAD risk loci (1p13.3, 1q41, 2q36.3, 6q25.1, 9p21.3, 10q11.21, and 15q22.33, respectively) in 3,320 subjects diagnosed with systolic heart failure of ischemic aetiology and participating in the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA) trial. The primary outcome was the composite of time to first event of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, secondary outcomes included mortality and hospitalization due to worsening heart failure. RESULTS: None of the 7 loci were significantly associated with the primary composite endpoint of the CORONA trial (death from cardiovascular cases, nonfatal myocardial infarction, and nonfatal stroke). However, the 1p13.3 locus (rs599839) showed evidence for association with all-cause mortality (after adjustment for covariates; HR 0.74, 95%CI [0.61 to 0.90]; P = 0.0025) and we confirmed the 1p13.3 locus (rs599839) to be associated with lipid parameters (total cholesterol (P = 1.1x10(−4)), low-density lipoprotein levels (P = 3.5 × 10(−7)) and apolipoprotein B (P = 2.2 × 10(−10))). CONCLUSION: Genetic variants strongly associated with CAD risk are not associated with the severity and outcome of ischemic heart failure. The observed association of the 1p13.3 locus with all-cause mortality requires confirmation in further studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12881-014-0140-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4412120
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44121202015-04-29 The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA) Haver, Vincent G Verweij, Niek Kjekshus, John Fox, Jayne C Wedel, Hans Wikstrand, John van Gilst, Wiek H de Boer, Rudolf A van Veldhuisen, Dirk J van der Harst, Pim BMC Med Genet Research Article BACKGROUND: Recent genome-wide association studies have identified multiple loci that are associated with an increased risk of developing coronary artery disease (CAD). The impact of these loci on the disease severity and prognosis of ischemic heart failure due to CAD is currently unknown. METHODS: We undertook association analysis of 7 single nucleotide polymorphism (rs599839, rs17465637, rs2972147, rs6922269, rs1333049, rs501120, and rs17228212) at 7 well established CAD risk loci (1p13.3, 1q41, 2q36.3, 6q25.1, 9p21.3, 10q11.21, and 15q22.33, respectively) in 3,320 subjects diagnosed with systolic heart failure of ischemic aetiology and participating in the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA) trial. The primary outcome was the composite of time to first event of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, secondary outcomes included mortality and hospitalization due to worsening heart failure. RESULTS: None of the 7 loci were significantly associated with the primary composite endpoint of the CORONA trial (death from cardiovascular cases, nonfatal myocardial infarction, and nonfatal stroke). However, the 1p13.3 locus (rs599839) showed evidence for association with all-cause mortality (after adjustment for covariates; HR 0.74, 95%CI [0.61 to 0.90]; P = 0.0025) and we confirmed the 1p13.3 locus (rs599839) to be associated with lipid parameters (total cholesterol (P = 1.1x10(−4)), low-density lipoprotein levels (P = 3.5 × 10(−7)) and apolipoprotein B (P = 2.2 × 10(−10))). CONCLUSION: Genetic variants strongly associated with CAD risk are not associated with the severity and outcome of ischemic heart failure. The observed association of the 1p13.3 locus with all-cause mortality requires confirmation in further studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12881-014-0140-3) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-21 /pmc/articles/PMC4412120/ /pubmed/25528061 http://dx.doi.org/10.1186/s12881-014-0140-3 Text en © Haver et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Haver, Vincent G
Verweij, Niek
Kjekshus, John
Fox, Jayne C
Wedel, Hans
Wikstrand, John
van Gilst, Wiek H
de Boer, Rudolf A
van Veldhuisen, Dirk J
van der Harst, Pim
The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
title The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
title_full The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
title_fullStr The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
title_full_unstemmed The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
title_short The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
title_sort impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the controlled rosuvastatin multinational trial in heart failure (corona)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412120/
https://www.ncbi.nlm.nih.gov/pubmed/25528061
http://dx.doi.org/10.1186/s12881-014-0140-3
work_keys_str_mv AT havervincentg theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT verweijniek theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT kjekshusjohn theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT foxjaynec theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT wedelhans theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT wikstrandjohn theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT vangilstwiekh theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT deboerrudolfa theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT vanveldhuisendirkj theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT vanderharstpim theimpactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT havervincentg impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT verweijniek impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT kjekshusjohn impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT foxjaynec impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT wedelhans impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT wikstrandjohn impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT vangilstwiekh impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT deboerrudolfa impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT vanveldhuisendirkj impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona
AT vanderharstpim impactofcoronaryarterydiseaserisklocionischemicheartfailureseverityandprognosisassociationanalysisinthecontrolledrosuvastatinmultinationaltrialinheartfailurecorona